SEngine Precision Medicine

Personalized Cancer Diagnostic/Drug Matching

SEngine Precision Medicine is accelerating drug development for cancer by using 3D organoid technology. Each patient’s cancer is a unique mosaic of genetic and epigenetic alterations necessitating different therapies for each patient. While DNA sequencing is cheap and quick to acquire for effective treatment options for solid tumors it predicts an estimated 15% of the time. Using their high-throughput technology, SEngine is testing more than 200 cancer drugs against a patient’s unique tumor organoid outside the body. In this manner, SEngine can identify the most effective and least toxic treatment option that DNA sequencing alone cannot reveal. By aggregating the results from several anonymized tests, SEngine can also leverage their data to develop new cancer-fighting drugs.